Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue

J Endocrinol. 2019 Aug;242(2):79-89. doi: 10.1530/JOE-18-0639.

Abstract

Obesity-associated chronic inflammation in adipose tissue is partly attributed to hypoxia with insufficient microcirculation. Previous studies have shown that exenatide, a glucagon-like peptide 1 (GLP-1) receptor agonist, plays an anti-inflammatory role. Here, we investigate its effects on inflammation, hypoxia and microcirculation in white adipose tissue of diet-induced obese (DIO) mice. DIO mice were injected intraperitoneally with exenatide or normal saline for 4 weeks, while mice on chow diet were used as normal controls. The mRNA and protein levels of pro-inflammatory cytokines, hypoxia-induced genes and angiogenic factors were detected. Capillary density was measured by laser confocal microscopy and immunochemistry staining. After 4-week exenatide administration, the dramatically elevated pro-inflammatory cytokines in serum and adipose tissue and macrophage infiltration in adipose tissue of DIO mice were significantly reduced. Exenatide also ameliorated expressions of hypoxia-related genes in obese fat tissue. Protein levels of endothelial markers and pro-angiogenic factors including vascular endothelial growth factor and its receptor 2 were augmented in accordance with increased capillary density by exenatide in DIO mice. Our results indicate that inflammation and hypoxia in adipose tissue can be mitigated by GLP-1 receptor agonist potentially via improved angiogenesis and microcirculation in obesity.

Keywords: GLP-1; angiogenesis; hypoxia; inflammation; obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue, White / blood supply
  • Adipose Tissue, White / drug effects*
  • Adipose Tissue, White / metabolism
  • Animals
  • Anti-Obesity Agents / administration & dosage
  • Anti-Obesity Agents / pharmacology
  • Cytokines / blood
  • Cytokines / genetics
  • Cytokines / metabolism
  • Diet, High-Fat / adverse effects
  • Exenatide / administration & dosage
  • Exenatide / pharmacology*
  • Gene Expression / drug effects
  • Hypoxia / genetics
  • Hypoxia / metabolism
  • Inflammation / genetics
  • Inflammation / metabolism
  • Inflammation / prevention & control*
  • Injections, Intraperitoneal
  • Male
  • Mice, Inbred C57BL
  • Microcirculation / drug effects*
  • Microcirculation / genetics
  • Microcirculation / physiology
  • Obesity / etiology
  • Obesity / genetics
  • Obesity / prevention & control*

Substances

  • Anti-Obesity Agents
  • Cytokines
  • Exenatide